Investing

Founded in 2009 and listed in 2011, Angkor Resources (TSXV:ANK,OTCQB:ANKOF) has developed a dual focus on energy and minerals across Asia and North America. Angkor Resources is advancing a dual-track strategy across energy and minerals.…

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) (‘Lobe Sciences’ or the ‘Company’) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation…

Alice Queen (AQX:AU) has announced Alice Queen raises $1M via issue of Convertible Notes Download the PDF here. This post appeared first on investingnews.com

Perth, Australia (ABN Newswire) – Locksley Resources Ltd (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) is pleased to advise that the Company is advancing a significant expansion to its exploration program, given the substantial increase in its landholding abutting…

Locksley Resources (LKY:AU) has announced Significant Enlargement of Exploration Program Download the PDF here. This post appeared first on investingnews.com

Carbonxt Group (CG1:AU) has announced Completion of Non-Renounceable Pro-Rata Entitlement Offer Download the PDF here. This post appeared first on investingnews.com

Newmont (TSX:NGT,NYSE:NEM,ASX:NEM) is preparing to withdraw from the TSX, the latest in a string of moves to streamline operations and rein in costs following its US$15 billion takeover of Newcrest Mining in 2023. The Denver-based…

Barrick Mining (TSX:ABX,NYSE:B) has agreed to sell its Hemlo gold mine in Ontario, Canada, for up to US$1.09 billion, continuing the company’s shift away from non-core assets. The company announced on Thursday (September 11) that…

(TheNewswire) Vancouver, British Columbia TheNewswire – September 15th, 2025 Prismo Metals Inc. (the ‘ Company ‘ ) (CSE: PRIZ,OTC:PMOMF) (OTCQB: PMOMF) is pleased to report that its exploration team has identified porphyry style mineralization at…

Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026 catalysts – MAVERIC Phase III…